SHERWIN I. RAY, et al., Plaintiffs-Appellants, v. CITIGROUP GLOBAL MARKETS, INC., et al., Defendants-Appellees.
No. 05-4362
United States Court of Appeals For the Seventh Circuit
ARGUED SEPTEMBER 7, 2006—DECIDED APRIL 12, 2007
Before RIPPLE, KANNE, and WOOD, Circuit Judges.
Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 03 C 3157—Matthew F. Kennelly, Judge.
I
The plaintiffs are more than a hundred retail investors who purchased millions of dollars’ worth of stock in SSOL between 2000 and 2002. SSOL was a small company in the wireless data services business. The value of its shares had soared during the late 1990s, going from less than $1 per share in early October 1999 to more than $170 in February 2000. By early April 2000, the price had settled down to a range between $70 and $90 per share. Defendant John Spatz is an institutional stockbroker employed by Citigroup (in an entity formerly known as Salomon Smith Barney, Inc.). Spatz worked with retail brokers Howard Borenstein, Mel Stewart, and Angelo Armenta, who in most cases were the people who directly advised the plaintiffs to buy SSOL stock. Citigroup is a global financial services firm that, as relevant here, provides investment and asset management services. Spatz, according to plaintiffs, was Citigroup‘s top institutional salesman, and thus his opinions carried great weight with others in the industry.
The plaintiffs alleged that Spatz, along with two other Citigroup stockbrokers (Francis X. Weber, Jr., and Anthony Louis DiGregorio, Jr., neither of whom was named as a defendant) fraudulently induced the plaintiffs to
According to the plaintiffs, what Spatz and Citigroup did not say was that SSOL had problems (about which it knew) with its current contracts with companies such as GoAmerica, Hutchison Telecom, and Sunday Telecommunications. Moreover, plaintiffs say, Spatz urged them to invest in SSOL to the exclusion of almost all other companies. (This may well have been poor portfolio design; whether it was fraud is a different question.) The information about research coverage lured plaintiffs into thinking that Citigroup (and Spatz) genuinely believed that SSOL was a safe investment and that there was little risk in directing their money to SSOL. In fact, according to plaintiffs, Citigroup thought no such thing and was well aware that SSOL was a risky investment. One clue might have been the fact, disclosed in SSOL‘s public filings, that
The district court found that the defendants were entitled to summary judgment. It looked to the Supreme Court‘s decision in Dura Pharmaceuticals, Inc. v. Broudo, 544 U.S. 336 (2005), for the elements of a claim under
- (1) a material misrepresentation (or omission);
- (2) scienter, i.e., a wrongful state of mind;
- (3) a connection with the purchase or sale of a security;
- (4) reliance, often referred to in cases involving public securities markets (fraud-on-the-market cases) as “transaction causation,” see Basic [Inc. v. Levinson, 485 U.S. 224,] 248-249 (nonconclusively presuming that the price of a publicly traded share reflects a material misrepresentation and that plaintiffs have relied upon that misrepresentation as long as they would not have bought the share in its absence);
- (5) economic loss; and
- (6) “loss causation,” i.e., a causal connection between the material misrepresentation and the loss.
II
On appeal, plaintiffs have pointed to evidence in the record that, they believe, provides that missing link. They acknowledge that the stock price of SSOL‘s competitors fell just as precipitously as the SSOL price, but they urge us to take another look at the evidence. The affidavits, depositions, and documentary evidence in the record reveal, they argue, that Spatz‘s and Citigroup‘s misrepresentations were the reason (plaintiffs’ emphasis) for the decline in SSOL‘s share price. This is because SSOL never had the contracts, revenues, or funding that Spatz repeatedly said that it did.
The question we must answer is whether this additional information was enough to show that the loss in value of SSOL‘s shares was proximately caused by the defendants’ alleged misrepresentations. See Dura, 544 U.S. at 343. As the Court explained in Dura, it is not enough to show that shares were purchased at a high price (whether inflated or not) and later sold at a much lower price. The reason is that many different factors might account for the drop in value:
If the purchaser sells later after the truth makes its way into the marketplace, an initially inflated purchase price might mean a later loss. But that is far from inevitably so. When the purchaser subsequently
resells such shares, even at a lower price, that lower price may reflect, not the earlier misrepresentation, but changed economic circumstances, changed investor expectations, new industry-specific or firm-specific facts, conditions, or other events, which taken separately or together account for some or all of that lower price.
544 U.S. at 342-43. If the plaintiff cannot prove “loss causation“—that is, the fact that the defendant‘s actions had something to do with the drop in value—then the claim must fail.
This court made the same point years before Dura in Bastian, where we wrote, “[W]hat securities lawyers call loss causation is the standard common law fraud rule . . . merely borrowed for use in federal securities fraud cases.” 892 F.2d at 683. This element of the claim attempts to distinguish cases where the misrepresentation was responsible for the drop in the share‘s value from those in which market forces are to blame. See Law v. Medco Research, Inc., 113 F.3d 781, 786-87 (7th Cir. 1997); Ryan v. Wersi Elec. GmbH & Co., 59 F.3d 52, 54 (7th Cir. 1995).
Although they try mightily to convince us otherwise, it seems to us that plaintiffs here are confusing loss causation, which we have just described, with transaction causation. Transaction causation is nothing but proof that a knowledgeable investor would not have made the investment in question, had she known all the facts. If the summary judgment record supports the plaintiff only on that point, and not on loss causation, then the defendant is entitled to prevail. As we said in Caremark, Inc. v. Coram Healthcare Corp., “[I]t [is] not sufficient for an investor to allege only that it would not have invested but for the fraud. Such an assertion alleges transaction causation, but it does not allege loss causation. Rather, it
There are several ways in which a plaintiff might go about proving loss causation. The first is sometimes called the “materialization of risk” standard. Caremark takes that approach, requiring the plaintiff to prove that “it was the very facts about which the defendant lied which caused its injuries.” 113 F.3d at 648. The second approach is the “fraud-on-the-market” scenario, which the Supreme Court discussed in Dura. Under that theory, plaintiffs must show both that the defendants’ alleged misrepresentations artificially inflated the price of the stock and that the value of the stock declined once the market learned of the deception. Finally, Bastian suggests that loss causation might be shown if a broker falsely assures the plaintiff that a particular investment is “risk-free.” 892 F.2d at 685-86. We explore these in turn to see if plaintiffs might have raised a genuine issue of material fact under one or more approach.
We can dispense quickly with the materialization of risk idea. There is no evidence in this record from which a jury could conclude that the drop in the value of the SSOL shares was attributable somehow to Spatz‘s or Citibank‘s alleged misrepresentations. The defendants introduced expert evidence that SSOL lost its value because of market forces, and the plaintiffs have offered nothing to rebut that theory—no expert testimony suggesting that the collapse was caused by the lack of the fraudulently promised contracts and financing, no evidence that companies similar to SSOL that had firm contracts survived. Plaintiffs’ only expert, David Cohen, considered only the amount of their damages, not the cause of those damages.
Plaintiffs similarly have not introduced enough evidence to go forward on a fraud-on-the-market theory. The record
The approach that comes closest to satisfying plaintiffs’ burden is the “risk-free” idea. In dicta, Bastian described this theory as follows:
Suppose a broker gives false assurances to his customer that an investment is risk-free. In fact it is risky, the risk materializes, the investment is lost. Here there can be no presumption that but for the misrepresentation the customer would have made an equally risky investment. On the contrary, the fact that the broker assured the customer that the investment was free of risk suggests that the customer was looking for a safe investment. Liability in such a case . . . is therefore consistent with nonliability in a case such as [Bastian].
892 F.2d 685-86. But the next sentences in Bastian indicate that it would be necessary for a broker to use very explicit language before loss causation could be proved this way. In Bastian, the plaintiffs had invested in oil and gas partnerships that lost value. We noted that “[t]he plaintiffs in the present case were not told that oil and gas partnerships are risk-free. They knew they were assuming a risk that oil prices might drop unexpectedly. They are
There is no evidence that Spatz and Citibank fraudulently assured the plaintiffs that the SSOL stock would survive the collapse in the market that the other stocks in that sector were experiencing. True, Spatz told the plaintiffs to hang onto their stock, saying things like “it was a certain money winner because Smith Barney was going to include it in all their divisions” and words to that effect. But this was against the backdrop of publicly available information suggesting that SSOL was, to put it charitably, a volatile stock, that had gone from less than $1 a share in 1999, to $170 a share in February 2000, to $80 a share in June 2000, back down to $1 a share by May or June of 2002. Spatz said nothing about how long someone would need to be prepared to hang onto the SSOL stock in order to reap the expected benefits, nor did he say anything about investments in the data services business being risk-free.
III
Defendants have also argued that the district court‘s judgment can be upheld on several alternative grounds:
A true Copy:
Teste:
Clerk of the United States Court of Appeals for the Seventh Circuit
USCA-02-C-0072—4-12-07
